Barriers to access to opioid medicines: A review of national legislation and regulations of 11 central and eastern European countries

The Lancet Oncology

Volumn 17, Issue 1, 2016, Pages e13-e22

  Vranken, Marjolein J M ^a   Lisman, John A ^b   Mantel Teeuwisse, Aukje K ^a   Jünger, Saskia ^c   Scholten, Willem ^b   Radbruch, Lukas ^d,e   Payne, Sheila ^f   Schutjens, Marie Hélène D B ^a,g  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Lisman Legal Life sciences ^*  (Netherlands)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e Malteser Hospital Bonn   (Germany)

^f LANCASTER UNIVERSITY   (United Kingdom)

^g Schutjens de Bruin   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT; CONTROLLED SUBSTANCE;

BULGARIA; CYPRUS; DRUG LEGISLATION; ESTONIA; GREECE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; HUNGARY; LATVIA; LITHUANIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PUNISHMENT; REVIEW; SERBIA; SLOVAKIA; SLOVENIA; SYSTEMATIC REVIEW; TURKEY (REPUBLIC); VALIDATION STUDY; COMPLICATION; EASTERN EUROPE; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; NEOPLASM; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUG MISUSE; TURKEY; WORLD HEALTH ORGANIZATION;

ANALGESICS, OPIOID; CONTROLLED SUBSTANCES; CYPRUS; EUROPE, EASTERN; GREECE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEGISLATION, DRUG; NEOPLASMS; OPIOID-RELATED DISORDERS; PAIN; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION DRUG MISUSE; TURKEY; WORLD HEALTH ORGANIZATION;

EID: 84955299055     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00365-4     Document Type: Review

References (50)

1. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012, 13:e58-e68. the European Palliative Care Research Collaborative (EPCRC), the European Association for Palliative Care (EAPC)the European Association for Palliative Care (EAPC).
2. WHO Model List of Essential Medicines 2015, WHO, World Health Organization, Geneva, (accessed July 8, 2015). http://www.who.int/medicines/publications/essentialmedicines/en/, 19th edn.
3. Duthey B, Scholten W Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage 2014, 47:283-297.
4. Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicines 2011, WHO, World Health Organization, Geneva, (accessed July 8, 2015). http://whqlibdoc.who.int/publications/2011/9789241564175_eng.pdf.
5. Report of the International Narcotic Control Board for 1999: freedom from pain and suffering 1999, International Narcotics Control Board, United Nations, (accessed July 8, 2015). https://www.incb.org/documents/Publications/AnnualReports/Thematic_chapters/English/AR_1999_E_Chapter_I.pdf.
6. Access to controlled medications programme, framework 2007, WHO, World Health Organization, Geneva, (accessed July 8, 2015). http://www.who.int/medicines/areas/quality_safety/AccessControlledMedicinesProgr.Framework.pdf.
7. Portenoy RK, Lesage P Management of cancer pain. Lancet 1999, 353:1695-1700.
8. "Please, do not make us suffer any more. . .": access to pain treatment as a human right 2009, Human Rights Watch, Human Rights Watch, New York, (accessed July 8, 2015). https://www.hrw.org/sites/default/files/reports/health0309web_1.pdf.
9. Cherny NI, Cleary J, Scholten W, Radbruch L, Torode J The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean, and the Middle East: introduction and methodology. Ann Oncol 2013, 24(suppl 11):xi7-x13.
10. Report of the International Narcotics Control Board for 1995: availability of opiates for medical needs 1995, International Narcotics Control Board, United Nations, (accessed July 8, 2015). http://www.incb.org/documents/Publications/AnnualReports/AR1995/AR_1995_E.pdf.
11. Cancer pain relief and palliative care: report of a WHO expert committee 1990, WHO, World Health Organization, Geneva, (accessed July 8, 2015). http://whqlibdoc.who.int/trs/WHO_TRS_804.pdf.
12. Cancer pain relief 1996, WHO, World Health Organization, Geneva, (accessed July 8, 2015). http://whqlibdoc.who.int/publications/9241544821.pdf, 2nd edn.
13. Single convention on narcotic drugs, 1961 (as amended by the 1972 protocol amending the single convention on narcotic drugs 1961, UN, United Nations, Geneva, (accessed Sept 6, 2015). http://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_en.pdf.
14. Merino JG Slowing the opioid analgesic overdose epidemic. BMJ 2013, 346:f730.
15. Rosenau AM Guidelines for opioid prescription: the devil is in the details. Ann Intern Med 2013, 158:843-844.
16. Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend 2014, 145:34-47.
17. Rutkow L, Chang HY, Daubresse M, Webster DW, Stuart EA, Alexander GC Effect of Florida's Prescription Drug Monitoring Program and Pill Mill laws on opioid prescribing and use. JAMA Intern Med 2015, 175:1642-1649.
18. Gomes T, Juurlink D, Yao Z, et al. Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. CMAJ Open 2014, 2:E256-E261.
19. Holmes D Prescription drug addiction: the treatment challenge. Lancet 2012, 379:17-18.
20. Fischer B, Keates A, Bühringer G, Reimer J, Rehm J Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?. Addiction 2014, 109:177-181.
21. Breivik H, Stubhaug A Burden of disease is often aggravated by opioid treatment of chronic pain patients: etiology and prevention. Pain 2014, 155:2441-2443.
22. Cleary J, Silbermann M, Scholten W, Radbruch L, Torode J, Cherny NI Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013, 24(suppl 11):xi51-xi59.
23. Cleary J, Radbruch L, Torode J, Cherny NI Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013, 24(suppl 11):xi24-xi32.
24. Cleary J, Simha N, Panieri A, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013, 24(suppl 11):xi33-xi40.
25. Cleary J, Radbruch L, Torode J, Cherny NI Next steps in access and availability of opioids for the treatment of cancer pain: reaching the tipping point?. Ann Oncol 2013, 24(suppl 11):xi60-xi64.
26. Report of the International Narcotics Control Board on follow-up to the twentieth special session of the General Assembly 2009, International Narcotics Control Board, United Nations, New York.
27. Recommendation Rec (2003) 24 of the committee of ministers to member states on the organisation of palliative care and explanatory memorandum Council of Europe, (accessed Sept 6, 2015). http://www.coe.int/t/dg3/health/Source/Rec(2003)24_en.pdf.
28. Vranken MJ, Mantel-Teeuwisse AK, Jünger S, et al. Legal barriers in accessing opioid medicines: results of the ATOME quick scan of national legislation of eastern European countries. J Pain Symptom Manage 2014, 48:1135-1144.
29. Cherny NI, Baselga J, de Conno F, Radbruch L Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 2010, 21:615-626.
30. Joranson DE, Ryan KM Ensuring opioid availability: methods and resources. J Pain Symptom Manage 2007, 33:527-532.
31. Liliana De Lima MH, Sakowski JA, Stratton Hill C, Bruera E Legislation analysis according to WHO and INCB criteria on opioid availability: a comparative study of 5 countries and the state of Texas. Health Policy 2001, 56:99-110.
32. Hungary Ministry of Health. Section 6(1), Ministry of Health Decree 43/2005 (X15) on the system for physician's prescriptions, trading in pharmacies, consumption, recording and storage at healthcare providers of medicinal products classified as controlled drugs.
33. Greece, Presidential Decree 148/2007, Article 1(6). The codification of the provisions stipulated in the regulatory decrees and ministerial orders regarding national legislation on drugs.
34. Bulgaria, Ordinance No 21, Article 13(3). The requirements for documentation and reporting during activities involving narcotic substances and their preparations. 2000.
35. Estonia, Regulation No 30, Section 3(4). The conditions and procedure for the issue of prescriptions for medicinal products and for the dispensing of medicinal products by pharmacies and the format of prescriptions (approved by Regulation No 30 of the Minister of Social Affairs on Feb 18, 2005 [RTL 2005, 23, 315], entered into force March 1, 2005).
36. Lithuania, Article 24.1, Order of the Minister of Health of the Republic of Lithuania No 112 (March 8, 2002). Medical prescriptions and disbursement (sale) of medicines. Official Gazette Valstybe˙s Žinios, March 16, 2002, no. 28, publication no. 1013.
37. Lithuania, Article 32, Order of the Minister of Health of the Republic of Lithuania No. 112 of March 8, 2002. Medical prescriptions and disbursement (sale) of medicines. Official Gazette Valstybe˙s Žinios, March 16, 2002, no. 28, publication no. 1013.
38. Slovenia, Article 38(2). Rules on classifying, prescribing and dispensing medicinal products for human use, 2008. Official Gazette of the Republic Slovenia: 86.
39. Lithuania, Article 4.9.4, Republic of Lithuania Government Resolution No 591 of May 30, 2005. The approval of the description of the procedure for monitoring the use of narcotic and psychotropic substances, consequences thereof, the circulation of the precursors of narcotic and psychotropic substances.
40. Lithuania, Article 4.10, Republic of Lithuania Government Resolution No. 591 of May 30, 2005. The approval of the description of the procedure for monitoring the use of narcotic and psychotropic substances, consequences thereof, the circulation of the precursors of narcotic and psychotropic substances.
41. Greece, Article 1(1), Act No. 3459/2006. Legal codes for drugs.
42. Serbia, Article 14. Rulebook on the prescription and dispensing of medicines (FRY Official Gazette, no. 16/94, 22/97, 52/02).
43. Bulgaria, Article 68 (2). Law for control over the narcotic substances and precursors, 1999.
44. ATOME legislation review workshop report, (accessed Aug 2, 2013). http://www.atome-project.eu/documents/atome_legislation_review_workshop.pdf.
45. Cleary J, Powell RA, Munene G, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013, 24(suppl 11):xi14-xi23.
46. Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol 2013, 24(suppl 11):xi41-xi50.
47. Mosoiu D, Ryan KM, Joranson DE, Garthwaite JP Reform of drug control policy for palliative care in Romania. Lancet 2006, 367:2110-2117.
48. ATOME conference report Estonia, (accessed April 22, 2015). http://www.atome-project.eu/documents/estonia-confrep.pdf.
49. Krakauer EL, Wenk R, Buitrago R, Jenkins P, Scholten W Opioid inaccessibility and its human consequences: reports from the field. J Pain Palliat Care Pharmacother 2010, 24:239-243.
50. Exploring current worst-case stories EAPC, (accessed Aug 26, 2015). http://www.eapcnet.eu/Themes/Policy/PragueCharter/Truestoriesfromtheworld.